HF  Cormorant Asset Management




     Office Locations:

200 Clarendon Street, 52nd Floor
Boston, MA 02116
Phone: 857-702-0370
Fax: 617-507-5905

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Cormorant manages a long/short public equity fund in healthcare, as well as a private equity/venture capital fund. According to an SEC filing, the firm has nearly $2B of assets under management. Bihua Chen, is the founder and portfolio manager of Cormorant Asset Management. Prior to founding Cormorant, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub-adviser to a large, multi-strategy hedge fund based in New York.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Bihua Chen CEO
    Edward Jay Scollins CFO and COO
    Nebojsa Obradovic CCO

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      03/06/2024


      Alumis


      CA


      $259,000,000


      Series C


      02/13/2024


      BioAge Labs


      CA


      $170,000,000


      Series D


      02/08/2024


      Neurona Therapeutics


      CA


      $120,000,000


      Venture


      08/23/2023


      Rapport Therapeutics


      MA


      $150,000,000


      Series B


      06/26/2023


      Myra Vision


      CA


      $25,000,000


      Series B


     

    Portfolio companies include:


      908 Devices
        web link


      Aerovate Therapeutics
        web link


      Akero Therapeutics
        web link


      Alumis
        web link


      Ambrx
        web link


      Apellis Pharmaceuticals
        web link


      Arkuda Therapeutics


      Artiva Biotherapeutics
        web link


      Atia Vision
        web link


      Atreca


      Avidity Biosciences
        web link


      AVROBIO
        web link


      Axonics Modulation Technologies
        web link


      Beam Therapeutics


      Bigfoot Biomedical
        web link


      BioAge Labs
        web link


      BioAtla
        web link


      BiVACOR
        web link


      BlossomHill Therapeutics
        web link


      C4 Therapeutics
        web link


      CARGO Therapeutics
        web link


      Centessa Pharmaceuticals
        web link


      Chroma Medicine
        web link


      Cibus
        web link


      Constellation Pharmaceuticals
        web link


      Design Therapeutics
        web link


      Electra Therapeutics
        web link


      Element Science
        web link


      Elevation Oncology
        web link


      Ensoma
        web link


      Erasca
        web link


      Expansion Therapeutics
        web link


      FogPharma
        web link


      Forma Therapeutics
        web link


      Freenome


      G1 Therapeutics


      Garuda Therapeutics
        web link


      Gelesis


      Greenlight Biosciences


      Iconic Therapeutics


      Icosavax


      ImmuneXcite
        web link


      Jounce Therapeutics
        web link


      Korro Bio
        web link


      Mersana Therapeutics


      Myra Vision
        web link


      Neurogene
        web link


      Neurona Therapeutics
        web link


      Olema Oncology
        web link


      Orchard Therapeutics


      Ovid Therapeutics
        web link


      Pliant Therapeutics
        web link


      Praxis Precision Medicines
        web link


      Precision BioSciences


      Pyxis Oncology


      Quanterix
        web link


      Rapport Therapeutics
        web link


      REGENXBIO
        web link


      Renovia
        web link


      Replimune
        web link


      Scholar Rock
        web link


      Shoreline Biosciences
        web link


      ShouTi
        web link


      Stoke Therapeutics
        web link


      Strata Oncology
        web link


      Syndax Pharmaceuticals
        web link


      Talaris Therapeutics
        web link


      Tango Therapeutics


      Tessera Therapeutics
        web link


      Tioga Medical
        web link


      TP Therapeutics
        web link


      Tricida


      Umoja Biopharma
        web link


      VelosBio
        web link


      Verve Therapeutics
        web link


      Vigil Neuroscience
        web link


      WaVe Life Sciences
        web link


      X4 Pharmaceuticals


     

    Recent News: